Terms: = Lymphoma AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954 AND Prognosis
527 results:
1. MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases.
Zhang LF; Zhang Y; Shui RH; Lu HF; Jiang WH; Cai X; Li XQ; Yu BH
Diagn Pathol; 2024 Apr; 19(1):60. PubMed ID: 38627702
[TBL] [Abstract] [Full Text] [Related]
2. Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions.
Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
[TBL] [Abstract] [Full Text] [Related]
3. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
Nylund P; Nikkarinen A; Ek S; Glimelius I
Front Immunol; 2024; 15():1373269. PubMed ID: 38566987
[TBL] [Abstract] [Full Text] [Related]
4. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
[TBL] [Abstract] [Full Text] [Related]
5. [Efficacy and prognosis of Chemotherapy Regimen Containing BTK Inhibitor in Treatment of Recurrent/Refractory Mantle Cell lymphoma].
Chen H; Liu XY; Chang Y; Chen ZQ; Li WQ; Zhang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):125-131. PubMed ID: 38387910
[TBL] [Abstract] [Full Text] [Related]
6. Anlotinib suppresses the DNA damage response by disrupting SETD1A and inducing p53-dependent apoptosis in Transformed Follicular lymphoma.
Zhuang X; Yao J; Li X; Jiang Y; Zhong M; Tan J; Zhou H; Li G; Zha J; Xu B
Int J Med Sci; 2024; 21(1):70-79. PubMed ID: 38164353
[No Abstract] [Full Text] [Related]
7. Broadening the horizon: potential applications of CAR-T cells beyond current indications.
Karsten H; Matrisch L; Cichutek S; Fiedler W; Alsdorf W; Block A
Front Immunol; 2023; 14():1285406. PubMed ID: 38090582
[TBL] [Abstract] [Full Text] [Related]
8. [The Clinical-Biological Features and prognosis of Patients with Mantle Cell lymphoma].
Chen WZ; Liu TB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1726-1732. PubMed ID: 38071052
[TBL] [Abstract] [Full Text] [Related]
9. Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell lymphoma: Results From the European Mantle Cell lymphoma Elderly Trial.
Hoster E; Delfau-Larue MH; Macintyre E; Jiang L; Stilgenbauer S; Vehling-Kaiser U; Salles G; Thieblemont C; Tilly H; Wirths S; Feugier P; Hübel K; Schmidt C; Ribrag V; Kluin-Nelemans JC; Dreyling M; Pott C;
J Clin Oncol; 2024 Feb; 42(5):538-549. PubMed ID: 37992261
[TBL] [Abstract] [Full Text] [Related]
10. Recent advances in genomics and therapeutics in mantle cell lymphoma.
Lu T; Zhang J; McCracken JM; Young KH
Cancer Treat Rev; 2024 Jan; 122():102651. PubMed ID: 37976759
[TBL] [Abstract] [Full Text] [Related]
11. Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
Ramsower CA; Rosenthal A; Robetorye RS; Mwangi R; Maurer M; Villa D; McDonnell T; Feldman A; Cohen JB; Habermann T; Campo E; Clot G; Bühler MM; Kulis M; Martin-Subero JI; Giné E; Cook JR; Hill B; Raess PW; Beiske KH; Reichart A; Hartmann S; Holte H; Scott D; Rimsza L
Br J Haematol; 2024 Jan; 204(1):160-170. PubMed ID: 37881141
[TBL] [Abstract] [Full Text] [Related]
12. The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response.
Yuan S; Zuo W; Liu T; Fu H
Technol Cancer Res Treat; 2023; 22():15330338231208608. PubMed ID: 37880950
[No Abstract] [Full Text] [Related]
13. Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial.
Bodet-Milin C; Morvant C; Carlier T; Frecon G; Tournilhac O; Safar V; Kraeber-Bodere F; Le Gouill S; Macintyre E; Bailly C
Sci Rep; 2023 Oct; 13(1):18177. PubMed ID: 37875524
[TBL] [Abstract] [Full Text] [Related]
14. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma.
Gerson JN; Handorf E; Villa D; Gerrie AS; Chapani P; Li S; Medeiros LJ; Wang M; Cohen JB; Churnetski M; Hill BT; Sawalha Y; Hernandez-Ilizaliturri FJ; Kothari S; Vose JM; Bast M; Fenske T; Rao Gari SN; Maddocks KJ; Bond D; Bachanova V; Kolla B; Chavez J; Shah B; Lansigan F; Burns T; Donovan AM; Wagner-Johnston N; Messmer M; Mehta A; Anderson JK; Reddy N; Kovach AE; Landsburg DJ; Glenn M; Inwards DJ; Ristow K; Karmali R; Kaplan JB; Caimi PF; Rajguru S; Evens A; Klein A; Umyarova E; Pulluri B; Amengual JE; Lue JK; Diefenbach C; Fisher RI; Barta SK
Blood Adv; 2023 Dec; 7(24):7393-7401. PubMed ID: 37874912
[TBL] [Abstract] [Full Text] [Related]
15. Resistance to PRMT5-targeted therapy in mantle cell lymphoma.
Long ME; Koirala S; Sloan S; Brown-Burke F; Weigel C; Villagomez L; Corps K; Sharma A; Hout I; Harper M; Helmig-Mason J; Tallada S; Chen Z; Scherle P; Vaddi K; Chen-Kiang S; Di Liberto M; Meydan C; Foox J; Butler D; Mason C; Alinari L; Blaser BW; Baiocchi R
Blood Adv; 2024 Jan; 8(1):150-163. PubMed ID: 37782774
[TBL] [Abstract] [Full Text] [Related]
16. BACH1 Loss Exerts Antitumor Effects on Mantle Cell lymphoma Cells via Inducing a Tumor-Intrinsic Innate Immune Response and Cell-Cycle Arrest.
Li G; Feng M; Zhang Z; Liu J; Zhang H
Mol Cancer Res; 2023 Dec; 21(12):1274-1287. PubMed ID: 37713314
[TBL] [Abstract] [Full Text] [Related]
17. Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-X
Beltrán-Visiedo M; Jiménez-Alduán N; Díez R; Cuenca M; Benedi A; Serrano-Del Valle A; Azaceta G; Palomera L; Peperzak V; Anel A; Naval J; Marzo I
Mol Oncol; 2023 Dec; 17(12):2507-2525. PubMed ID: 37704591
[TBL] [Abstract] [Full Text] [Related]
18. CDK9 Inhibitor Induces Apoptosis, Autophagy, and Suppression of Tumor Growth in Adult T-Cell Leukemia/lymphoma.
Kato N; Kozako T; Ohsugi T; Uchida Y; Yoshimitsu M; Ishitsuka K; Aikawa A; Honda SI
Biol Pharm Bull; 2023; 46(9):1269-1276. PubMed ID: 37661406
[TBL] [Abstract] [Full Text] [Related]
19. Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia.
Aroldi A; Mauri M; Ramazzotti D; Villa M; Malighetti F; Crippa V; Cocito F; Borella C; Bossi E; Steidl C; Scollo C; Voena C; Chiarle R; Mologni L; Piazza R; Gambacorti-Passerini C
J Cell Mol Med; 2023 Oct; 27(20):3053-3064. PubMed ID: 37654003
[TBL] [Abstract] [Full Text] [Related]
20. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and
Rodrigues JM; Hollander P; Schmidt L; Gkika E; Razmara M; Kumar D; Geisler C; Grønbæk K; Eskelund CW; Räty R; Kolstad A; Sundström C; Glimelius I; Porwit A; Jerkeman M; Ek S
Haematologica; 2024 Apr; 109(4):1171-1183. PubMed ID: 37646663
[TBL] [Abstract] [Full Text] [Related]
[Next]
